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The role of Clusterin in attenuation of inflammation and reverse cholesterol transfer makes
this molecule a potential candidate as a marker for cancer, cardiovascular disease, diabe-
tes mellitus, and metabolic syndrome. In elderly subjects cardiovascular diseases represent
the primary cause of death and different clinical studies have shown a positive correlation of
these diseases with changes in the lipid pattern. This work aimed at evaluating the relation-
ship between circulating clusterin and the biochemical parameters that characterize the
lipid profile of a Sardinian population divided into five age groups including centenarians;
the high frequency in Sardinia of these long-lived individuals gave us the opportunity to ex-
tend the range of the age groups to be analyzed to older ages and to better evaluate the
changes in the lipid balance during ageing and its relationship with clusterin concentration
in plasma. Our results showed that Clusterin concentration values of the youngest group
were more similar with the centenarian’s group compared to the other age groups, and a
positive correlation arises with LDL. Furthermore given the high prevalence of cardiovascu-
lar diseases in the population examined and the association of Clusterin with these patholo-
gies we evaluated Clusterin concentration variation in two groups with or without
cardiovascular diseases. In presence of cardiovascular disease, Clusterin is significantly re-
lated to the most atherogenic components of lipid profile (total cholesterol and LDL), espe-
cially in women, suggesting its potential role in modulating cardiovascular metabolic
risk factors.
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Introduction
Clusterin (CLU)/Apo J is a glycoprotein of 70–80 kDa, it is a disulfide linked heterodimer com-
posed of α and β subunits generated by a single cleavage from the protein precursor. It was
originally identified in ram rete testis fluid, and later on it was found to be expressed in
several tissues and in all human fluids [1]. It is present in plasma as a soluble protein or as a
component of a lipid-poor subclass of high-density lipoproteins (HDLs) of molecular mass of
70–200 kDa [2,3]. Recent proteomic analyses revealed that CLU is also bound to LDL and very
LDLs [4–6]even if the role in these lipoproteins is unknown. Clusterin has been reported to be
implicated in several physiological processes such as sperm maturation, lipid transportation,
complement inhibition, tissue remodeling, membrane recycling, cell-cell and cell-substratum
interaction, stabilization of stressed proteins in a folding-competent state and promotion or in-
hibition of apoptosis. CLU is ubiquitously expressed in most cells and tissues, and is upregu-
lated under a variety of pathological conditions including ageing, diabetes, atherosclerosis,
degenerative diseases [7–9], moreover it has recently drawn much attention because of its asso-
ciation with cancer promotion and metastasis [10–12]. CLU can exist within the cell to func-
tion in either proapoptotic or prosurvival processes. This diverse set of functions can be
attributed to the existence of two alternatively spliced forms of the Clu gene that encode secre-
tory CLU (sCLU) or nuclear CLU (nCLU). The sCLU form seems to be cytoprotective [13]
while nCLU migrates to the nucleus on cytotoxic stress to trigger cell death [14,15]. Although
its exact function has not been clearly defined, there is increasing evidence that CLU is induced
by stress and functions as a cytoprotective extracellular chaperone similar to small heat shock
proteins [16–18]. During in vivo ageing Clu gene expression was found to increase from gesta-
tion to adults in humans [19], in the human pituitary gland [20], in the rat ventral prostate
[21], in human glial cultures [22] and in human lymphocytes [23]. In serum sCLU levels seems
to increase during in vivo ageing at least in males [8]. During vascular damage sCLU was
found to accumulate in the human serum of diabetes type II patients or during myocardial in-
farction [8]; sCLU accumulates in the artery wall during atherosclerosis [24] and is present in
human and mouse atherosclerotic lesions, but not in normal arterial tissue [25,26]. In tissue
cultures it acts as an acceptor of cholesterol from macrophage-derived foam cells suggesting
that CLU, present at high concentrations around stressed cells, has the potential to remove
cholesterol from damaged cell membranes and then deliver it to HDL particles for subsequent
disposal through reverse cholesterol transport [27]. In another work ApoJ was find to co-
localize with E-LDL in atherosclerotic lesions and may thus subserve protective functions
through its capacity to inactivate C5b-9 complement complexes and by reducing the cytotoxic
effects of modified LDL on cells that gain contact with the lipoprotein [28]. Recent experiments
by Martinez-Bujidos et al., performed with CLU-depleted LDLs demonstrated that CLU plays
an active protective role against LDL aggregation [29]. Moreover in a recent work fasting plas-
ma clusterin levels were found to be positively correlated with BMI, a parameter of whole body
adiposity in healthy adults [30]. The purpose of this study was to evaluate clusterin concentra-
tion in plasma samples of a Sardinian population divided into five age groups with a consistent
number of centenarians, as well as the concentration of the biochemical parameters that char-
acterize the lipid profile of an individual, including high-density lipoprotein (HDL), low-
density lipoprotein (LDL), triglycerides and total cholesterol, in order to establish if any rela-
tionship can be found between circulating clusterin and those parameters. Furthermore, since
almost half of the population analysed suffered from cardiovascular diseases, which are the
most common diseases between elderly people, and considering that several studies hold that
CLU is implicated in various cardiovascular diseases (e.g. atherosclerosis, coronary heart dis-
ease and myocardial infarction) [26,31–34] the same correlation analyses mentioned above
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Subjects for this study were recruited through the AKeA project that studies the Sardinian cen-
tenarians [35,36]. The AKeA project has been approved by the Bioethic Committee of the Uni-
versity of Sassari and ASL N°1 Sassari. The major criteria for the selection of the partecipants
were the chronological age, the residence in Sardinia (the majority of them being people com-
ing from the same villages of centenarians) and the apparently healthy status. An informed
written consent, approved by the above mentioned Bioethic Committee, was obtained from
each subject or from a legally responsible family member. A standardized questionnaire on
general information was also administered concerning gender, age, smoking habits, alcohol
drinking, medications and health status (Table 1). Smoking was defined as smoking at least
one cigarette a day and lasting more than six months. Alcohol drinking was defined as drinking
any type of alcoholic beverage at least once a week and lasting more than six months. Smoking
and drinking were classified as current (yes) previous (ex smoker/drinker) or never (no smok-
er/drinker). Hypertension was defined according to repeated blood pressure
measurements 140/90 mmHg or previous diagnosis of hypertension and antihypertensive
treatment. Almost half of the population (47.2%) had cardiovascular diseases which is the most
common disease between elderly people (cardiovascular diseases were grouped as arterial hy-
pertension (41.5%), angina (4.5%), heart failure (4.1%), myocardial infarction (1.2%), other
cardiac diseases (1.6%; valvular diseases or cardiomyopathies)) while a minority of them suf-
fered from chronic conditions (5.3%, epatic 15.8%, respiratory 11.4%, nervous systems 7.3%,
tumors 8.5%, endocrine metabolic disorders 25.6%, cerebrovascular diseases 7.7%). Table A in











Β-blockers (%) 1.4 0 58.5 31.3 32.4
ACE-inhibitors (%) 1.4 0 5.7 0 0
Ca-inhibitors (%) 0 0 26.4 16.7 14.7
Angiotensin II-antagnists (%) 0 2 15.1 10.4 14.7
Vasodilators (%) 0 0 11.3 4.2 0
Diuretics (%) 0 0 13.2 6.3 4.4
Statins (%) 0 4 20.8 18.8 14.7
Antiplatelet drugs 0 0 3.8 0 0
Smokers %
No 54.5 87.5 63.5 61.7 71.2
Yes 36.4 12.5 3.8 8.5 6.1
Ex 9.1 0.0 32.7 29.8 22.7
Drinkers (%)
No 92.3 12.5 3.8 8.5 6.1
Yes 7.7 0.0 32.7 29.8 22.7
Ex 0.0 66.7 46.2 42.6 24.2
doi:10.1371/journal.pone.0128029.t001
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S1 File shows the same data stratified by age groups. The population with 264 subjects was di-
vided into 5 age groups (20–50 years (y): N = 53, 60–75y N = 49, 80–89y N = 48, 90–99y
N = 46,100y N = 68) for the age related analysis, while to examine the relationship with car-
diovascular diseases the population was divided into two groups with or without cardiovascular
diseases (N = 116, N = 148, respectively).
Biochemical Parameters
Blood samples were collected in EDTA-coated tubes for clusterin analyses, and processed with-
in two hour. The red cell fraction was then separated by centrifugation at 2500g at 4°C for 15
min and the clear plasma supernatant was stored in aliquots frozen at -80°C. For cholesterol,
LDL, triglycerides and HDL blood was collected into gel vacutainer tubes and their concentra-
tion were assessed through enzymatic method using the ARCHITECT cSystems. Creatinine,
Glucose and Urea with the ARCHITECT c8000 using enzymatic methods. For clusterin con-
centration in plasma a competitive ELISA kit (AdipoGen, Korea) was used following manufac-
turer instructions. All the statistical analyses were performed using SPSS v21 and MedCalc
v12.7 softwares. The differences between groups were assessed through the Kruskal Wallis test
followed by pairwise comparison Dunn’s test; for the correlation analyses the Spearman test
was used. A p-value< 0.05 was considered statistically significant.
Results
In this paper we wanted to evaluate if Clusterin concentration changes during ageing and if a
relationship exists with changes in the biochemical parameters characterizing the lipid profile
of an individual such as high-density lipoprotein (HDL), low-density lipoprotein (LDL), tri-
glycerides and total cholesterol. Table 2 shows the values of the parameters mentioned above
in the population analyzed divided by age groups as previously described and the significant
differences highlighted by Kruskal Wallis test. This analysis revealed a significant change in
concentration for all of the parameters analyzed. Cholesterol, LDL and Triglycerides had an
higher value in the group of 80–89years while in the older groups their level was lower
(Table 2, Fig 1). HDL had the highest value in the group of 20–50 years with lower values in
the other four groups. Clusterin had higher values in the group of 90–99 years while the group
Table 2. Clusterin and biochemical parameter’s concentrations by Age group and Kruskal Wallis test for comparisons between the five age
groups.
Age group
20–50 years (N = 53) 60–75 years (N = 49) 80–89 years (N = 48) 90–99 years (N = 46) 100–196 years (N = 68) K-W testc
Median IQRa Median IQRa Median IQRa Median IQRa Median IQRa p-value
Clusterin (μg/ml) 30.42 (24.34–48.29) 48.94 (37.12–64.86) 47.52 (38.64–60.96) 50.59 (35.52–61.40) 44.37 (31.45–55.41) <0.0001
Total Cholesterol (mg/dL) 189 (168–214) 209 (190–241) 218.50 (199–258) 186.50 (172–223) 184.50 (162–199.5) <0.0001
HDL (mg/dL)b 68 (54–78) 55 (44–63) 55 (47.5–69.5) 47.50 (38.5–60) 49 (39–57) <0.0001
LDL (mg/dL)b 99.0 (89.2–126) 130.3 (113–159.5) 138.50 (119–166.5) 112.0 (99–140) 107.8 (95–130) <0.0001
Triglycerides (mg/dL) 74 (56–141) 107 (83–132) 123.5 (96.5–146.5) 119.5 (90–140) 105 (82–138) 0.001
Glucose (mg/dL) 83 (73–93) 87 (84–99) 85 (58–95) 87.5 (79–108) 91 (82–110) 0.062
Urea (mg/dL) 4.3 (3.6–5.3) 4.6 (4.1–5.6) 5.7 (3.9–6.3) 5.3 (3.45–7.10) 5 (3.7–6.4) 0.329
Creatinine (mg/dL) 0.8 (0.75–0.9) 0.80 (0.7–0.9) 1.10 (0.85–1.3) 1 (0.7–1.6) 1 (0.9–1.3) 0.0001
a IQR, interquartile range
bHDL, high density lipoprotein cholesterol; LDL, low density lipoprotein cholesterol
cK-W = Kruskal Wallis test
doi:10.1371/journal.pone.0128029.t002
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of centenarians had CLU values lower compared to the other elderly groups (Table 2, Fig 2),
the pairwise comparisons test in the Supplementary data shows the p-values relative to the
comparisons by pair groups (Table B in S1 File) highlighting how the youngest group has clus-
terin values statistically more similar to the centenarian’s group. No significative differences
emerged between the five age groups for the other biochemical parameters evaluated (glucose,
urea and creatitìnine) (Table 2). Considering the whole population the correlation analyses
with the Spearman’s test showed that clusterin is positively correlated with LDL cholesterol
(ρ = 0.196 p = 0.002) (Table 3) and the evaluation of gender differences revealed statistically
significant correlations only in the females group, in particular a positive correlation
between CLU and LDL (ρ = 0.29, p = 0.001) and a negative correlation between CLU and HDL
(ρ = -0.183, p = 0.031) (Table 3). Dividing the population in the five age groups the correlation
between CLU and LDL is concentrated only inside the group of 90–99 years old (ρ = 0.403,
Fig 1. Lipid parameters’ values in the five age groups. Boxplots represent the Lipid parameters analysed
in the five age groups, total cholesterol, LDL (low density lipoprotein), HDL (high density lipoprotein) and
Triglycerides. Circles represent outliers and asterix extreme outliers.
doi:10.1371/journal.pone.0128029.g001
Fig 2. Clusterin concentration values in the five age groups. Boxplots represent the Clusterin
concentration values in the five age groups. Circles represent outliers.
doi:10.1371/journal.pone.0128029.g002
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p = 0.006) (Table 4). Since the population analyzed had an high number of individuals with
cardiovascular diseases and considering the association of Clusterin with different pathologies
related to cardiovascular diseases we wanted to see if any difference existed between the two
groups in the concentration values of both clusterin and lipid parameters. Table 5 shows how
only triglycerides values were significantly different. For concentration values divided by age
with or without cardiovascular diseases and relative p-values for comparisons see Table C in S1
File. The correlation analyses showed a stronger correlation with LDL (ρ = 0.30 p = 0.002) and
other two correlations emerged, with total cholesterol and with triglycerides (ρ = 0.258
p = 0.007, ρ = 0.234 p = 0.014) but only inside the group of people that had cardiovascular dis-
eases, while no significant correlation came out inside the healthier group (Table 5). When
considering gender differences only females with cardiovascular diseases showed a positive cor-
relation between CLU and LDL (ρ = 0.432 p = 0.001) and with total cholesterol (ρ = 0.406
p = 0.001) (Table 6).
Discussion
The role of clusterin in attenuation of inflammation and reverse cholesterol transfer makes this
molecule a potential candidate as a marker for cancer, cardiovascular diseases, diabetes
Table 3. Correlations between Clusterin and Lipid parameters in the whole population and divided by gender.
Clusterin
All (N = 264) Gender
Male (N = 123) Female (N = 141)
ρa p-value ρa p-value ρa p-value
Total Cholesterol 0.087 0.159 0.073 0.429 0.124 0.142
HDLb -0.117 0.062 -0.037 0.695 -0.183 0.031
LDLb 0.196 0.002 0.099 0.302 0.290 0.001
Triglycerides 0.073 0.240 0.124 0.176 0.038 0.656
aρ, Spearman's rank correlation coefﬁcient
bHDL, high density lipoprotein cholesterol; LDL, low density lipoprotein cholesterol;
doi:10.1371/journal.pone.0128029.t003
Table 4. Correlation between Clusterin and Lipid parameters divided by Age groups.
Clusterin
Age group
20–50y ((N = 53) 60–75y (N = 49) 80–89y (N = 48) 90–99y (N = 46) 100–106y
(N = 68)
ρa p-value ρa p-value ρa p-value ρa p-value ρa p-value
Total Cholesterol -0.322 0.069 0.117 0.429 0.105 0.476 0.243 0.104 -0.116 0.351
HDLb -0.137 0.327 -0.084 0.575 -0.128 0.409 0.059 0.702 -0.026 0.839
LDLb -0.255 0.065 0.159 0.287 0.227 0.138 0.403 0.006 -0.112 0.401
Triglycerides -0.102 0.469 0.096 0.518 -0.035 0.812 -0.070 0.644 0.070 0.575
aρ, Spearman's rank correlation coefﬁcient
bLDL, low density lipoprotein cholesterol; HDL, high density lipoprotein cholesterol;
doi:10.1371/journal.pone.0128029.t004
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mellitus, and metabolic syndrome. In elderly subjects cardiovascular diseases represent the pri-
mary cause of death. Different epidemiological and clinical studies have shown that the inci-
dence of atherosclerosis related vascular diseases is positively correlated with changes in the
lipid pattern [37,38] highlighting the importance of cardiocirculatory conditions on human
survival. The results obtained for Clusterin concentration in our population agreed in part with
the data shown in literature by the work of Trougakos et al., where an increase of this protein
during ageing occurs until 90 [8,31]. The novelty of this work is that our investigations spanned
over older people showing an increase even after 90 years, but in centenarians, which have a
life-long survival advantage [29,30], the clusterin values are lower compared to the other elder-
ly groups. Until now, only one work has focused the attention on clusterin expression in cente-
narians [39], in particular Trougakos et al., found that clusterin gene expression level in
lymphocyte samples of 25 centenarians was reduced as compared to elderly donors. Our work
highlights for the first time the reduction of clusterin in plasma samples of centenarians at the
protein level and fill the gap in the age range 90–99years. This behavior can be related, as al-
ready hypothesized by Trougakos et al.[39], to the clusterin function as a sensitive biosensor of
environmental insults and particularly oxidative stress. Centenarians are considered as a model
of successful ageing characterized by low ROS (reactive oxygen species) load [40], so, its
Table 5. Clusterin and lipid parameters concentrations by presence or absence of cardiovascular diseases and Kruskal Wallis test for compari-
sons between the two groups.
Cardiovascular diseases
No (N = 148) Yes (N = 116) K-W testc
Median IQRa Median IQRa p-value
Clusterin (μg/ml) 44.84 (32.99–60.97) 46.87 (36.02–58.88) 0.244
Total Cholesterol (mg/dL) 194.50 (173–218.5) 201.00 (177–231) 0.359
HDL (mg/dL)b 52.00 (43–64) 52.00 (42–63) 0.626
LDL (mg/dL)b 116.50 (97.5–140.5) 122.00 (102–143) 0.614
Triglycerides (mg/dL) 99.50 (75–126) 119.00 (90–152) 0.001
a IQR, interquartile range
bHDL, high density lipoprotein cholesterol; LDL, low density lipoprotein cholesterol
cK-W = Kruskal Wallis test
doi:10.1371/journal.pone.0128029.t005
Table 6. Correlation between Clusterin and Lipid parameters in the two groups with or without cardiovascular diseases and divided by gender.
Clusterin
Cardiovascular diseases Cardiovascular diseases by gender








ρa p-value ρa p-value ρa p-value ρa p-value ρa p-value ρa p-value
Total Cholesterol -0.027 0.770 0.258 0.007 0.042 0.745 -0.044 0.734 0.100 0.487 0.406 0.001
HDLb -0.086 0.353 0.037 0.706 -0.014 0.913 -0.148 0.264 0.036 0.811 0.006 0.964
LDLb .0052 0.582 0.300 0.002 0.035 0.800 0.115 0.380 0.151 0.311 0.432 0.001
Triglycerides -0.066 0.470 0.234 0.014 0.017 0.898 -0.118 0.367 0.236 0.098 0.224 0.086
aρ, Spearman's rank correlation coefﬁcient
bHDL, high density lipoprotein cholesterol; LDL, low density lipoprotein cholesterol
doi:10.1371/journal.pone.0128029.t006
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reduction can be attributable to the lower ROS load of centenarians. Determination of oxida-
tive stress biomarkers in plasma together with clusterin levels can be important to support this
interesting hypothesis raised by Franceschi et al. Considering the two groups with or without
cardiovascular diseases no statistically significant difference in clusterin concentration values
were detectable. CLU involvement in reverse cholesterol transport and its potential protective
role in atherogenesis through its binding to enzymatically modified low-density lipoprotein
and its capacity to reduce fatty acid mediated cytotoxicity lead us to investigate the relationship
of this protein with the lipid profile of the population analyzed. These analyses highlighted a
positive correlation between Clusterin and LDL cholesterol. Dividing the population by gender
the positive correlation appears only in the females group with an higher correlation value than
the one detected for the whole population; furthermore, a negative association with HDL was
found in this group. The association between CLU levels and LDL has been demonstrated for
the first time by Aronis et al. in a population of young healthy individuals [41], but this group
found a positive correlation even for total cholesterol. This work confirms the positive correla-
tion found by Aronis et al. for LDL cholesterol extending the result to an higher age range.
Moreover it highlighted gender differences revealing a stronger correlation for females between
Clusterin and LDL-cholesterol. It has been reported that androgen, a member of sex hormone
influences clusterin secretion [42], hence, hormone regulation can be a reason for the gender
differences observed in the present work. Dividing the population in the five age groups the
correlation between CLU and LDL is concentrated only inside the group of 90–99 years old.
One reason for not having found a significant correlation in the other age groups can be related
the small sample size. Ageing is a multifactorial process modulated by the interplay among ge-
netic and environmental factors [43] and is associated with multiple, systemic dysfunctions of
the body and accompanied by lipid metabolism disorders that in turn lead to more chronic
medical conditions [44]. One of the leading cause of death in the elderly population are cardio-
vascular diseases and the association with dyslipidemia rises substantially with advancing age
[45]. For this reason and considering the high number of people with cardiovascular diseases
in our sample population, (see materials and methods for details on how they have been gath-
ered) we made separate analyses for the presence or absence of cardiovascular diseases. The re-
sults of theses analyses showed a positive correlation between CLU and LDL only in the group
with cardiovascular diseases and stronger than in the whole population. Moreover other lipid
parameters besides LDL (total cholesterol and triglycerides) came out to be significantly corre-
lated to CLU. In a recently published paper Martinez-Bujidos et al., provided evidence that
CLU plays an active protective role against LDL aggregation and they proposed that the in-
creased expression of CLU in atherosclerotic lesions could be a response of the arterial walls to
LDL aggregation, the initial step of atherosclerosis [29]. These findings could be a possible ex-
planation to the positive correlation obtained between CLU and LDL only inside the group
with cardiovascular diseases if we consider that CLU changes can be the result of its action of
counteracting the proatherogenic function of LDL through a prevention of their aggregation.
The correlations highlighted by this work suggest a gender dependent lipid metabolism regula-
tion in which clusterin protein may be involved and hence supports the hypothesis of its role in
the disease mechanisms. Further investigations would be addressed to elucidate the molecular
mechanisms involved in such regulation. During ageing usually an increase in total cholesterol
levels occurs in both genders, while in advanced aging (octogenarians, nonagenarians), people
show a lipid profile typical of low risk of atherosclerotic disease [46], with high HDL, low total
cholesterol and low LDL and high HDL/total cholesterol ratio [47,48] compared with septuage-
narians [48,49]. Epidemiological studies found that the plasma levels of HDL cholesterol de-
crease with increasing age, but in the elderly they are unchanged or slightly increased [50]. A
paper by Baggio et al. reported that the mean HDL levels of centenarians (both males and
Plasma Clusterin and Lipid Profile in Ageing
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females) are 20% lower than those of 65-year-old subjects [51]. The decreased levels of HDL
can be due to inflammatory, hormonal and metabolic changes which are more prevalent with
aging, while a possible explanation to the higher levels of HDL seen in some population in el-
derly people can be due to the decreased levels of androgens in aging men which result in an in-
crease of HDL particles due to the reduced catabolism driven by testosterone [44]. In our
sample population there is an evident change in the lipid profile with significant differences in
the five age groups for all lipid parameters (Table 2). In our population an increase of total cho-
lesterol and LDL cholesterol occurs from 20 to 89 years, while in nonagenarians and centenari-
ans their level decreases but at values that are considered to be in the normal range (186.5mg/
dL and 184mg/dL for nonagenarians and centenarians respectively) while different studies
have reported that very low levels of total cholesterol are associated with an all-cause mortality
[52,53]. The low values of total cholesterol and LDL can be important in reaching a lipid bal-
ance capable of preventing the occurrence of cardiovascular diseases. HDL levels, whose higher
values are usually correlated with lower cardiovascular risk, were slightly lower if compared to
the other groups. but at the same time the concentration values were above 40mg/dL which is
desirable according to the ATP III guidelines [54]. In conclusion, the positive correlation
found between Clusterin and the most atherogenic components of lipid profile (total cholester-
ol and LDL), highlights the importance that this protein can have in modulating the lipid bal-
ance of an individual especially during aging where visible changes in the lipid parameters
occur, and in cardiovascular diseases where the absolute risk associated with dyslipidemia rises
with advancing age [45].
Supporting Information
S1 File. Distribution of the diseases by age group in the population analyzed (Table A). Pai-
wise comparisons between the five age groups (Table B). Clusterin and lipid parameters con-
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